Daunorubicin-Lance

Daunorubicin-LENS

Country of origin: Russia
Pharm-Group: Antitumor antibiotics

Manufacturers: Lance-Pharm (Russia)
International name: Daunorubicin
Synonyms: Daunozom, Rubomycin hydrochloride, Cerubidin
Dosage forms: lyophilized powder for the preparation of injection solution 40 mg, lyophilized powder for the preparation of injection solution 20 mg
Composition: Active ingredient - daunorubicin.

Indications for use: Acute leukemia, blast crisis of chronic myeloid leukemia, uterine chorionepithelioma, lymphosarcoma, malignant histocytosis; soft tissue sarcoma, neuroblastoma (in children). Used in combination with other antitumor drugs as part of remission induction programs.

Contraindications: Hypersensitivity, suppression of bone marrow function, terminal stages of the tumor process, metastases to the bone marrow, cachexia, leukopenia, thrombocytopenia, viral infections (varicella, herpes zoster), organic heart damage, severe liver and kidney dysfunction, gastric ulcer and duodenum in the acute stage, pregnancy, lactation. Restrictions on use: old age, gout or kidney stones in history.

Side effects: Nausea, vomiting (noted after administration and lasting up to 48 hours), esophagitis or stomatitis (3-7 days after use), oropharyngeal candidiasis, anorexia, diarrhea, ulceration of the mucous membranes of the gastrointestinal tract, tenesmus; cardiotoxic effect in the form of congestive heart failure (tachycardia, shortness of breath, swelling of the feet and ankles) and in the form of pericarditis-myocarditis, leukopenia, thrombocytopenia, anemia, granulocytopenia; unusual bleeding or hemorrhage; hyperuricemia or nephropathy associated with increased production of uric acid (pain in the joints, lower back or side); reddish color of urine (disappears within 48 hours), cystitis; hair loss (reversible), darkening or redness of the skin, panniculitis, cellulite; allergic reactions (skin rash, itching, swelling, fever or chills); headache, opportunistic infections; extravasation, tissue necrosis, phlebitis at the injection site.

Interaction: Reduces the anti-gout effectiveness of allopurinol, colchicine and sulfinpyrazone. Other anticancer drugs and radiation therapy potentiate the effect and additively inhibit bone marrow function; cyclophosphamide may increase cardiotoxicity. When live viral vaccines are administered, replication of the vaccine virus and increased side effects are possible; inactivated vaccines may result in a decrease in the production of antiviral antibodies.

Overdose: Symptoms: manifestations of cardiotoxicity (pain in the heart, tachycardia, ECG changes, decreased blood pressure, myocarditis), severe myelosuppression (granulocytopenia), weakness, nausea, vomiting. Treatment is symptomatic.

Special instructions: The use of daunorubicin should be carried out under strict monitoring of blood counts. Before each course of treatment, the functions of the heart, kidneys and liver should be assessed. To prevent the development of secondary hyperuricemia, early use of allopurinol and sufficient fluid intake during treatment are recommended. Use with caution in patients with insufficient bone marrow reserve. Dental interventions should, if possible, be completed before starting therapy or postponed until the blood count normalizes. It is necessary to avoid getting the solution under the skin or into soft tissues. If extravasation occurs (burning or acute pain at the injection site), administration should be stopped immediately and resumed in another vein until the full dose is administered. During the treatment period, vaccinations with viral vaccines should not be performed. If the powder or solution accidentally gets on the skin or mucous membranes, they should be washed thoroughly with soap and water. The liposomal form of daunorubicin citrate can be mixed